VERA Vera Pharma: רווח למניה בשנים עשר החודשים האחרונים

Vera Therapeutics, Inc. (VERA) utilizes an asset-light model with outsourced manufacturing and implements robotic protein screening to accelerate testing. Net income per share over the last four quarters illustrates the efficiency of these processes, with the indicator reaching -5.88. Consequently, the company develops targeted molecules that block the pathological immune response in severe kidney diseases.
פילוחים אנליטיים ודוחות נתונים של חברת Vera Therapeutics, Inc. (VERA)

Net income per share (TTM) measures the final return of each security over a year, allowing investors to evaluate business capitalization efficiency and real cash flow growth rates. By analyzing the specific profit levels of Vera Therapeutics, Inc. (VERA) over 12 months, one can diagnose the company's transition toward monetizing innovative molecules for kidney treatment, which are protected by strong patent barriers in the orphan segment.